The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Open accessAbstract
BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up. RESULTS: Of six primary variables, two correlated significantly with infection risk: the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of HIV-1 envelope proteins (Env) correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 per 1-SD increase; P=0.02; q=0.08), and the binding of plasma IgA antibodies to Env correlated directly with the rate of infection (estimated odds ratio, 1.54 per 1-SD increase; P=0.03; q=0.08). Neither low levels of V1V2 antibodies nor high levels of Env-specific IgA antibodies were associated with higher rates of infection than were found in the placebo group. Secondary analyses suggested that Env-specific IgA antibodies may mitigate the effects of potentially protective antibodies. CONCLUSIONS: This immune-correlates study generated the hypotheses that V1V2 antibodies may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have mitigated the effects of protective antibodies. Vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Self-citationCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Self-citationProfound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., et al. (2011) · Nature · doi:10.1038/nature10003 · Cited by 988
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationVaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465
Self-citationPreserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys
Letvin, N. L., Mascola, J. R., Sun, Y., Gorgone, D. A., Buzby, A. P., Xu, L., Yang, Z.-Y., Chakrabarti, B., Rao, S. S., Schmitz, J. E., et al. (2006) · Science · doi:10.1126/science.1124226 · Cited by 372
Self-citationGilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428405 · Cited by 355
Self-citationExposure stratified case-cohort designs.
Borgan, Ø., Langholz, B. M., Samuelsen, S. O., Goldstein, L. J., & Pogoda, J. M. (2000) · Lifetime Data Analysis · doi:10.1023/a:1009661900674 · Cited by 286
Ferrari, G., Pollara, J., Kozink, D., Harms, T., Drinker, M., Freel, S., Moody, M. A., Alam, S. M., Tomaras, G. D., Ochsenbauer, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00171-11 · Cited by 233
Self-citationA Framework for Assessing Immunological Correlates of Protection in Vaccine Trials
Qin, L., Gilbert, P. B., Corey, L., McElrath, M. J., & Self, S. G. (2007) · The Journal of Infectious Diseases · doi:10.1086/522428 · Cited by 206
Self-citationImmune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
Letvin, N. L., Rao, S. S., Montefiori, D. C., Seaman, M. S., Sun, Y., Lim, S.-Y., Yeh, W. W., Asmal, M., Gelman, R. S., Shen, L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002351 · Cited by 184
Self-citationForthal, D. N., Gilbert, P. B., Landucci, G., & Phan, T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6596 · Cited by 179
Self-citationNew Paradigms for HIV/AIDS Vaccine Development
Picker, L. J., Hansen, S. G., & Lifson, J. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-042010-085643 · Cited by 160
Górny, M. K., Stamatatos, L., Volsky, B., Revesz, K., Williams, C. A. U., Wang, X., Cohen, S., Staudinger, R., & Zolla‐Pazner, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5232-5237.2005 · Cited by 148
Self-citationNawaz, F., Cicala, C., Ryk, D. V., Block, K. E., Jelicic, K., McNally, J. P., Ogundare, O., Pascuccio, M., Patel, N., Wei, D., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001301 · Cited by 144
Nitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de Souza, M. S., Morgan, P., Polonis, V. R., Benenson, M. W., VanCott, T., Ratto‐Kim, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/422258 · Cited by 139
Self-citationBarnett, S. W., Srivastava, I. K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A. D., Ferrai, M. G., Weiss, D. E., Letvin, N. L., Montefiori, D. C., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282f3ca57 · Cited by 111
Self-citationIgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms.
Griffiss, J. M., & Goroff, D. K. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.6.2882 · Cited by 109
Mestecky, J. F., Moro, I., Kerr, M. A., & Woof, J. M. (2005) · Elsevier eBooks · doi:10.1016/b978-012491543-5/50013-9 · Cited by 106
Karnasuta, C., Paris, R., Cox, J. H., Nitayaphan, S., Pitisuttithum, P., D, P. T. M., Brown, A. E., Gurunathan, S., Tartaglia, J., Heyward, W. L., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.028 · Cited by 101
Self-citationJarvis, G. A., & Griffiss, J. M. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.6.1962 · Cited by 98
Barnett, S. W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., zur Megede, J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02533-09 · Cited by 82 · cited 2×
“of infections) Placebo Low response Medium response High response 6267 (0) 2111 (0) 2312 (0) 2563 (0) 6199 (24) 2105 (6) 2304 (8) 2560 (3) 6127 (11) 2099 (6) 2302 (2) 2556 (4) 693 (13) 210 (4) 180 (6) 264 (2)”
Changela, A., Wu, X., Yang, Y., Zhang, B., Zhu, J., Nardone, G. A., O'Dell, S. J., Pancera, M., Górny, M. K., Phogat, S. K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02335-10 · Cited by 54
Self-citationEvaluating Immune Correlates in HIV Type 1 Vaccine Efficacy Trials: What RV144 May Provide
Rolland, M., & Gilbert, P. B. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0240 · Cited by 42
Self-citationCommentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl
Gilbert, P. B., Hudgens, M. G., & Wolfson, J. A. (2011) · The International Journal of Biostatistics · doi:10.2202/1557-4679.1341 · Cited by 25
Self-citation
Cited by
HIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationDeeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Metadata
- Authors
- Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., Liao, H.-X., DeVico, A. L., Lewis, G. K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y., Rao, M., Billings, E., Karasavvas, N., Robb, M. L., Ngauy, V., de Souza, M. S., Paris, R., Ferrari, G., Bailer, R. T., Soderberg, K. A., Andrews, C., Berman, P. W., Frahm, N., De Rosa, S. C., Alpert, M. D., Yates, N. L., Shen, X., Koup, R. A., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N. L., & Kim, J. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-04-05
- Volume
- 366
- Issue
- 14
- Pages
- 1275-1286
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143421242
- Cited by
- 1,808
- References
- 29
- FWCI
- 87.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.